Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease
Abstract
Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition. Understanding within‐person biomarker(s) change over time is critical for trial enrollment and design.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 24, 2018
- Source ID
- 10.1016/j.jalz.2018.01.012
Entities
People
- Anne M. Fagan
- Chengjie Xiong
- Courtney L. Sutphen
- David M. Holtzman
- Elizabeth M. Herries
- Jack H. Ladenson
- Lena Mccue
- On Behalf Of Adni
Organizations
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- United States Department of Defense
- Washington University in St. Louis